Trevi Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Trevi Therapeutics (TRVI).

Price Target Range — 11 Quarters

Analyst Consensus — 15 Analysts

1S.Buy

14Buy

Consensus RatingBuy# Analysts15Avg. Consensus PT$22Upside to Avg. PT+63.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 14, 2026	Jones Trading	Debanjana Chatterjee	PT Raise	Buy	$24→$28
Aug 7, 2026	Oppenheimer	Leland Gershell	PT Raise	Outperform	$24→$25
Aug 7, 2026	Cantor Fitzgerald	Josh Schimmer	PT Raise	Overweight	$25→$30
Jul 21, 2026	BMO Capital	Connor Murphy	Initiate	Outperform	$36
Jul 20, 2026	B. Riley Securities	Mayank Mamtani	PT Raise	Buy	$21→$31
Jul 20, 2026	HC Wainwright & Co.	Brandon Folkes	PT Raise	Buy	$21→$24
May 20, 2026	Needham	Serge Belanger	Maintained	Buy	$23
May 6, 2026	HC Wainwright & Co.	Brandon Folkes	Maintained	Buy	$21
May 6, 2026	Needham	Serge Belanger	PT Cut	Buy	$24→$23
Apr 17, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$19
Mar 19, 2026	Jones Trading	Debanjana Chatterjee	PT Cut	Buy	$25→$24
Mar 18, 2026	Morgan Stanley	Judah Frommer	PT Cut	Overweight	$19→$18
Mar 18, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$19
Mar 18, 2026	Needham	Serge Belanger	PT Raise	Buy	$22→$24
Mar 9, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$19
Mar 9, 2026	HC Wainwright & Co.	Brandon Folkes	Maintained	Buy	$21
Jan 9, 2026	HC Wainwright & Co.	Brandon Folkes	Maintained	Buy	$21
Jan 8, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$19
Dec 19, 2025	Stifel	Annabel Samimy	PT Raise	Buy	$15→$18
Nov 20, 2025	Leerink Partners	Faisal Khurshid	PT Raise	Outperform	$13→$16

Analyst Ratings News

PRO
Jones Trading Maintains Buy on Trevi Therapeutics, Raises Price Target to $28

Jones Trading analyst Debanjana Chatterjee maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and raises the price target from $24 to $28.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Trevi Therapeutics, Raises Price Target to $25

Oppenheimer analyst Leland Gershell maintains Trevi Therapeutics (NASDAQ:TRVI) with a Outperform and raises the price target from $24 to $25.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Maintains Overweight on Trevi Therapeutics, Raises Price Target to $30

Cantor Fitzgerald analyst Josh Schimmer maintains Trevi Therapeutics (NASDAQ:TRVI) with a Overweight and raises the price target from $25 to $30.

Benzinga Newsdesk

This Fortinet Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Tuesday

Wall Street analysts upgraded Fortinet, Goldman Sachs, Adaptive Biotechnologies, and Five Below, with positive outlooks and raised price targets.

Avi Kapoor

This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top Wall Street analysts change outlook on top stocks. For analyst rating changes, see https://www.benzinga.com/analyst-stock-ratings. INSM initiated with $192 PT.

Avi Kapoor

PRO
BMO Capital Initiates Coverage On Trevi Therapeutics with Outperform Rating, Announces Price Target of $36

BMO Capital analyst Connor Murphy initiates coverage on Trevi Therapeutics (NASDAQ:TRVI) with a Outperform rating and announces Price Target of $36.

Benzinga Newsdesk

Trevi Therapeutics Inc

Trevi Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Jones Trading Maintains Buy on Trevi Therapeutics, Raises Price Target to $28

PRO
Oppenheimer Maintains Outperform on Trevi Therapeutics, Raises Price Target to $25

PRO
Cantor Fitzgerald Maintains Overweight on Trevi Therapeutics, Raises Price Target to $30

This Fortinet Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Tuesday

This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

PRO
BMO Capital Initiates Coverage On Trevi Therapeutics with Outperform Rating, Announces Price Target of $36

People Also Watch

People Also Watch

Trevi Therapeutics Inc

Trevi Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROJones Trading Maintains Buy on Trevi Therapeutics, Raises Price Target to $28

PROOppenheimer Maintains Outperform on Trevi Therapeutics, Raises Price Target to $25

PROCantor Fitzgerald Maintains Overweight on Trevi Therapeutics, Raises Price Target to $30

This Fortinet Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Tuesday

This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

PROBMO Capital Initiates Coverage On Trevi Therapeutics with Outperform Rating, Announces Price Target of $36

People Also Watch

People Also Watch

PRO
Jones Trading Maintains Buy on Trevi Therapeutics, Raises Price Target to $28

PRO
Oppenheimer Maintains Outperform on Trevi Therapeutics, Raises Price Target to $25

PRO
Cantor Fitzgerald Maintains Overweight on Trevi Therapeutics, Raises Price Target to $30

PRO
BMO Capital Initiates Coverage On Trevi Therapeutics with Outperform Rating, Announces Price Target of $36